Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

MLA

Noonan, Anne M., et al. “Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.” Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 24, no. 6, June 2016, pp. 1150–58. EBSCOhost, https://doi.org/10.1038/mt.2016.66.

APA

Noonan, A. M., Farren, M. R., Geyer, S. M., Huang, Y., Tahiri, S., Ahn, D., Mikhail, S., Ciombor, K. K., Pant, S., Aparo, S., Sexton, J., Marshall, J. L., Mace, T. A., Wu, C. S., El-Rayes, B., Timmers, C. D., Zwiebel, J., Lesinski, G. B., Villalona-Calero, M. A., & Bekaii-Saab, T. S. (2016). Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy : The Journal of the American Society of Gene Therapy, 24(6), 1150–1158. https://doi.org/10.1038/mt.2016.66

Chicago

Noonan, Anne M, Matthew R Farren, Susan M Geyer, Ying Huang, Sanaa Tahiri, Daniel Ahn, Sameh Mikhail, et al. 2016. “Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.” Molecular Therapy : The Journal of the American Society of Gene Therapy 24 (6): 1150–58. doi:10.1038/mt.2016.66.